Skip to main content

WELTRUZA™ receives FDA Approval  •  View webcast replay

Hit enter to search or ESC to close
Close Search
MedincellMedincellMedincell
search
Menu
  • About Us
    • Impact companyPurposeful innovation coupled with a responsible company model can positively impact Global Health
    • Our peopleOur strength: valuing and nurturing our team’s entrepreneurial spirit, expertise, and dedication
    • Leadership TeamSeasoned leaders unite to tackle global health challenges
  • Science
    • UZEDY®Relapse prevention long-acting treatment for schizophrenia
    • WELTRUZA™Once-monthly long-acting olanzapine for adults with Schizophrenia.
    • R&D PipelineAdvancing therapeutic care with precision Delivery
    • BEPO® TechnologyOur technology platform to develop long-acting treatments
    • PublicationsFacilitate collaboration with our collection of scientific articles and presentations
  • Responsibility
    • Our commitmentsTransforming global health with purposeful innovation
    • Code and policiesHigh standards for all company’s stakeholders
    • 2026 ESG reportSocial and environmental information about the company and its activities
  • Careers
    • Our vision & our valuesSee how our HR vision and values shape a dynamic workforce
    • Work environment & benefitsExplore the benefits and environment driving our team’s success
    • Join usEmbark on a career journey where your talents meet opportunity
  • News & events
    • NewsroomLatest updates and announcements, the gateway to all press releases
    • EventsEarnings calls, conferences, General Meeting: live and replay
  • Investors
    • OverviewAll information and news about Medincell stock
    • Reports & regulated informationFinancial reports, operational updates, and shareholder information
    • General MeetingAll documents related to the Medincell Shareholders’ Meetings
    • Leadership teamSeasoned leaders unite to tackle global health challenges
  • Contact
  • EN
  • FR
  • search
Category

Bepo

Improving in vivo release prediction from in situ forming depots with a novel flow-through in vitro dissolution apparatus

August 20, 2025
August 20, 2025

Ultrasensitive In Vitro and Ex Vivo Tracking of 13C-Labeled PEG–PLA Degradation Products by MALDI-TOF Mass Spectrometry

October 23, 2024
October 23, 2024

Revisiting the nature and pharmacodynamics of tacrolimus metabolites

September 27, 2024
September 27, 2024

In Vitro and In Vivo Hydrolytic Degradation Behaviors of a Drug-Delivery System Based on the Blend of PEG and PLA Copolymers

November 27, 2023
November 27, 2023

Poster for European Congress of Clinical Microbiology and Infectious Diseases 2023

April 15, 2023
April 15, 2023

Evaluating the in vivo stability of water-soluble PEG-PLA copolymers using FRET imaging

March 25, 2023
March 25, 2023

Proof-of-concept study for a long-acting formulation of ivermectin injected in cattle as a complementary malaria vector control tool

February 14, 2023
February 14, 2023

Long-acting injectable formulation technologies: Challenges and opportunities for the delivery of fragile molecules

July 28, 2022
July 28, 2022

Intra-articular delivery of full-length antibodies through the use of an in situ forming depot

December 12, 2021
December 12, 2021

Evaluation of Loco-Regional Skin Toxicity Induced by an In Situ Forming Depot after a Single Subcutaneous Injection at Different Volumes and Flow Rates in Göttingen Minipigs

August 26, 2021
August 26, 2021
  • 1
  • 2
  • Next

Articles récents

  • Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)
  • Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan
  • Investor Webcast – WELTRUZA™ FDA Approval
  • General Meeting 2026 (French)
  • Medincell Announces Resumption of Trading in Its Shares on Euronext Paris as of 2:45pm

Commentaires récents

No comments to show.

About us

Impact company
Our people
Leadership Team

Science

UZEDY®
WELTRUZA™
R&D Pipeline
BEPO® Technology
Publications

Careers

Our vision & our values
Work environment & benefits
Join us

Responsability

Our commitments
Code and policies
2026 ESG report

News & events

Newsroom
Events

Investors

Overview
Reports & regulated information
General Meeting
Leadership team

Ressources & contact

Contact
Ethics line
Legal notices
Privacy policy

© 2026 Medincell. All rights reserved.

Website by ScreenUp

Close Menu
  • Home
  • About Us
    • Impact company
    • Our people
    • Leadership team
  • Science
    • UZEDY®
    • WELTRUZA™
    • R&D Pipeline
    • BEPO® Technology
    • Publications
  • Responsibility
    • Our commitments
    • Code and policies
    • 2025 ESG Report
  • Careers
    • Our vision & our values
    • Work environment & benefits
    • Join us
  • News & events
    • News
    • Events
  • Investors
    • Overview
    • Regulated information
    • General Meeting
    • Leadership team
  • Contact
  • FR